Service Development: Clinician training and eLearning module Staff training:

Key clinical staff members were identified and their specific training needs explored to tailor the more appropriate method of training.

Table 1: Staff who received formal training prior to the start of study

Breast team	Gynae Team	Colorectal	Other
		team	
6 Oncologists	4 Nurse	6 Research	26 Nurses Outpatients
4 Research	specialists	nurses	and Chemo suite
nurses	3 Research	5 Oncologists	10 Nurse practitioners
4 Nurse	nurses	3 pre-	6 Pharmacists
specialists	3 Oncologists	assessment	5 Oncologists
2 Admin staff		nurses	3 Research staff LCRF
		Chemo lead	5 Nescalon stan LON
		nurse	
		1	

Prior to training written materials were produced in the form of a trainer prompt sheet, staff training manual and one page staff prompt sheets which were distributed to all relevant clinical areas as a guide in how to access the patient reported results within the EHR.



eRAPID Staff training prompt sheet

Introduction of staff facilitating training

- Introductions
- · Ask staff to complete training log
- · Overview of objectives of training session
 - Aim to describe the eRAPID research programme and RCT in systemic cancer treatment
 - Provide practical demonstration of the eRAPID system on the computer (internet and PPM)
- Show certificates
- Discuss request for eRAPID champion (communication link) with opportunity to attend eRAPID update meetings.

BACKGROUND

What is eRAPID?

- eRAPID stands for Electronic patient self-Reporting of Adverse-events:
 Patient Information and aDvice. This is a 5 year programme grant funded by the NIHR (£1.9 million). This is being conducted by POCPRG led by Prof Galina Velikova
- eRAPID is an online system for patients to report information about their symptoms and side effects during cancer treatment. Patients can complete questions about their symptoms from home or in the hospital via a website. We will be asking patients to complete this at least weekly and when unwell for 18 weeks of their chemotherapy treatment. The questionnaire asks questions specific to the patients cancer diagnosis to reflect different symptoms (Gynae, Breast or G.I) The system:



- Provides patients with immediate advice on how to self-manage mild/low level problems
- o Informs patients when to contact the hospital for severe symptoms
- Is linked to PPM to allow for patient reported data to be included in medical records for staff to use to monitor patients throughout treatment
- Can send email alerts to staff to notify them of severe symptoms. (This will be sent to nurse specialists)

IMPORTANT

eRAPID IS NOT A REPLACEMENT FOR USUAL CARE

eRAPID is a project we have been working on and developing for the last 4 years with funding for NIHR. During this time we

- developed the patient symptom questionnaires- (based on the CTCAE criteria for assessing chemotherapy toxicity)
- devised the eRAPID website, collated self-management advice for low level symptoms
- set up the IT infrastructure to allow for patient questionnaire data to be transferred into PPM from an online questionnaire website
- conducted testing in the breast cancer clinic with 14 patients receiving chemotherapy
- Patients and oncology staff were involved in all steps of the development of eRAPID taking part in interviews, choosing symptom questions, advising on the website and participating in usability testing.

eRAPID RCT in systemic cancer treatment January 2015- December 2017

- Does eRAPID work in clinical practice?
- The study is randomised with half of the patients using the online system.
- The disease groups covered will be (Adj Breast, Adj G.I. and Gynae)



- We are hoping to recruit 84 patients to the pilot stage of the study and 484 in the main study.
- The overall aims of the eRAPID system are to improve the safe delivery of cancer treatments, enhance patient care and standardise documentation of adverse events (AE) within the clinical datasets.

Potential benefits of eRAPID:

Benefits for patients

- Earlier symptom detection and improved self-management, timely admissions
- o Improved supportive medication use
- Appropriate hospital/GP/community contacts
- Better outcomes (improved symptom control, functioning and quality of life

Benefits for staff

- o Reduce the number of hospital/GP/community contacts
- Save time spent on enquiring and recording AEs
- Focus attention during clinical contacts on most important/sever AEs
- o Support decision making in routine care

• Benefits to the NHS

 eRAPID provides a cost-effective approach to supporting patient selfmanagement and reducing hospital/GP contacts

PRACTICAL DEMONSTRATION

How does eRAPID work?

QTool and eRAPID website

Practical demonstration of patient symptom questionnaire and how staff access results. (Also how to access alert report for those responding to alerts)



· Logging onto website and QTool.-

https://qtool.leeds.ac.uk/Account/ParticipantLogOn/LTHT

Username: Demo Password: demo

- 1st demo complete mild/moderate symptom responses to activate selfmanagement advice
- 2nd demo complete severe symptom responses to show alert message for contacting hospital
- · Show website advice

PPM

Using patients (007 and 023) from breast usability study as example eRAPID QTool data demonstrate:

- Accessing results on PPM (graphs and tabulated results)
- Show cycle graphs on Usability patients and go through refining results.
 (patient 007)
- Show how to access alert report for those staff receiving e-mail alerts.
- How to respond to an alert (specifically for Breast CNS, Gynae CNS). Still go
 through this process with other teams highlighting they have the option to
 respond if they have had contact with a patient.
- Request staff document in PPM their annotation if patient contact them as a result of completing the eRAPID questionnaire.

How to use PPM results

- Encourage clinicians to report back to patients that they have seen the eRAPID toxicity. Show the patients the graphs or the table. Go through it
- Thank you for reporting your symptoms. I can see you had xxxxx, tell me more about this, when, how did you deal with it?
- Have you got any other problems/symptoms?



eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice

eRAPID RCT in systemic cancer treatment Staff training guide

Version 1.0 January 2014

Thank you for your help with the eRAPID research study. This guide provides an overview of eRAPID, the RCT in systemic treatment, information on accessing patient reported symptoms in PPM

The guide is divided into the following sections:

- 1. What is eRAPID?
- 2. Why and how was eRAPID developed?
- 3. How does eRAPID work?
- 4. Accessing patients symptom report information in PPM
- 5. Using patient reported information- An example from the eRAPID usability testing
- 6. The eRAPID RCT in systemic cancer treatment: What is expected of me?
- 7. Frequently asked questions

To contact the eRAPID research team please:	
Email:	
Telephone:	
Psychosocial Oncology & Clinical Practice Research Group	

1. What is eRAPID?

- eRAPID stands for Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice
- eRAPID is a 5 year programme grant of £1.9million funded by the National Institute for Health Research (NIHR). The research is being conducted by the Psychosocial Oncology and Clinical Practice Research Group (Level 3 Bexley Wing), led by Professor Galina Velikova.
- eRAPID is an online system (see Figure 1) for patients to report information about their symptoms and side effects during cancer treatment. Patients can complete questions about their symptoms from home or in the hospital via a website. The system:
 - Provides patients with immediate advice on how to self-manage mild/low level problems
 - o Informs patients when to contact the hospital for severe symptoms
 - Is linked to PPM to allow for patient reported data to be included in medical records for staff to use to monitor patients throughout treatment
 - Can send email alerts to staff to notify them of severe symptoms
- The overall aims of the eRAPID system are to improve the safe delivery of cancer treatments, enhance patient care and standardise documentation of adverse events (AE) within the clinical datasets.
- In the 5 year research programme we aim to assess the value of eRAPID in clinical practice.

We hypothesise that eRAPID has the potential to bring benefit to patients, staff and the NHS in the following ways:


- Benefits for patients
 - o Earlier symptom detection and improved self-management, timely admissions
 - o Improved supportive medication use
 - o Appropriate hospital/GP/community contacts
 - o Better outcomes (improved symptom control, functioning and quality of life
- · Benefits for staff
 - o Reduce the number of hospital/GP/community contacts

- o Save time spent on enquiring and recording AEs
- Focus attention during clinical contacts on most important/sever AEs
- o Support decision making in routine care

• Benefits to the NHS

 eRAPID provides a cost-effective approach to supporting patient self-management and reducing hospital/GP contacts

Figure 1. Overview of the eRAPID system



2. Why and how was eRAPID developed?

Why?

- Systemic drug treatments for cancer are often associated with acute and long term adverse events (AE).
- Severe AEs can escalate to hospitalisation for potentially life-threatening toxicities: 18% of cancer patients present to emergency services within 14 days of a scheduled hospital visit for symptom management (infection, fever, nausea/vomiting, pain, breathlessness)
- Many patients however, delay seeking emergency care especially out of hours
- AE are documented consistently by physicians in clinical trials however in routine care recording of AE by clinicians and reporting by patients is variable and often omitted and this may be a factor in preventable fatalities
- The need for monitoring of cancer treatment AE is at odds with a health care system relying increasingly on patient self-management and home based care. In order to bridge the gap in service provision to detect, identify and manage AE in cancer patients we have developed the eRAPID system
- In our previous research in Leeds the Psychosocial Oncology and Clinical Practice
 research group have shown that electronic reporting of patient-reported outcome measures
 (PROMs) has proven extremely acceptable to patients in the clinic setting

How?

- Between 2010-2013 the eRAPID developmental work was conducted (funded by an NIHR programme development grant), which focused on
 - Building the online system for patient reporting of AE and linking this information into the electronic patient records (PPM)
 - Exploring the cancer teams and care pathways to establish where eRAPID would best fit within these.

- Selecting and adapting the symptom questions that could be understood by patients and clinicians and mapped onto the Common Terminology Criteria for Adverse Events (CTCAE) severity grades already used by clinical teams.
- Collating patient information and advice for managing the common symptoms and side effects of systemic cancer treatment and putting this information on the eRAPID website.

Staff and patients have played a vital role in the development of the eRAPID system throughout the past 4 years by taking part in interviews, choosing symptom questions, advising on the website and participating in usability testing


- In 2013 the NIHR awarded Professor Galina Velikova the 5 year programme grant to assess the value of eRAPID in clinical practice.
- Early in 2014 we conducted a testing exercise of the full eRAPID system
 - 14 breast cancer patients receiving adjuvant chemotherapy agreed to assist with the testing. Patients were given access to the eRAPID symptom reporting questionnaire and eRAPID website at the start of treatment.
 - The clinical nurse specialists and oncologists involved in patient care were trained to access the patient reports in PPM.
 - Feedback from both staff and patients and patients was predominately very positive and the comments and advice received helped to refine the intervention further.
 - Patients have felt the system is easy to use and provides valuable information about managing the symptoms and side effects of treatment.


Figure 2. Comments from breast cancer patients involved in the eRAPID testing phase




3. How does eRAPID work?


- o In this section we describe how eRAPID works from the patients' perspective.
- Patient participants consenting to the eRAPID study will be asked to complete the symptom questionnaires by logging in via the eRAPID website http://erapid.leeds.ac.uk/










Questions will appear on the page one at a time.









 When all the eRAPID questions are completed the system will provide advice for the symptoms that have been reported to be a problem. For serious symptoms, patients will be advised to immediately call the medical team at the hospital to speak to someone about the problem.



 For less serious symptoms the system will provide some advice for helping patients selfmanage these issues. Information on all symptoms and side effects is available on the eRAPID website.




In addition the eRAPID website http://erapid.leeds.ac.uk/, includes advice on managing general and specific issues patients may experience during cancer treatment



After completing the questionnaires patients can see their results presented as graphs so they can monitor their results over time.




When you have completed the questionnaire more than once, your results are displayed as




The patient reported symptom information is immediately passed into their electronic medical record in PPM


4. Accessing patients' symptom report information in PPM




You can change the number of questionnaire results you can see by using the refine the results functions...




When a patient has reported a severe symptom that has generated an alert this will appear at the top of their QTool page:




Clicking on the 'Record response to alert' button will lead to the following page...



An additional alert response can be added or previous information can be edited or removed if required...




Resolved alerts will then appear in green text...





Using patient reported information- An example from the eRAPID usability testing

- Routinely collecting patient reports of their symptoms throughout treatment can help staff
 see how symptoms and side effects change over time and may help to identify key
 problems for discussion during chemotherapy review consultations. We hope eRAPID data
 will be a valuable tool in consultations in conjunction with a discussion with the patient
- Below are some screenshots from PPM showing QTool data for a patient who helped with testing eRAPID in 2014 whilst receiving chemotherapy.
- The symptom questionnaire scores match the severity of the CTCAE- higher scores = worse toxicity
- Patients can report additional symptoms that are not routinely asked about in the standard questionnaire but this information will only appear in the tables not the graphs



The patient reported information can also be viewed in a table:





Some advice on using the information during consultations and discussions with patients:

- Please remember to tell the patient you are using or have looked at the symptom reports they have provided
- The patient information is most useful if it has been completed regularly (we are asking eRAPID study participants to complete the questionnaire on a weekly basis). Patients are more likely to complete the symptom questionnaire if they see it is being used by staff.
- The information should be used to guide conversations with patients- feel free to ask
 patients to clarify their answers and check whether your interpretation of the results
 matches that of the patient.

6. The eRAPID RCT in systemic cancer treatment

Timeframe

Recruitment will take place from January 2015- December 2017.

Eligible patients

Adult patients attending St James' University Hospital Bexley Wing with

- · early breast or colorectal cancer requiring adjuvant systemic treatment or
- gynaecological cancer requiring chemotherapy

Sample and study design

- We aim to recruit a maximum of 568 patients to the study.
- This will be a prospective randomised parallel group design study with repeated measures and mixed methods and will include an internal pilot phase.
- Participants will be randomised (following a 1:1 randomisation strategy) to receive the eRAPID intervention or usual care.

Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment. Hospital staff will be able to review eRAPID reports and use the information in the decision-making process when seeing patients in clinic or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.

Study outcome measures

This study will use several outcomes to compare the eRAPID intervention with usual care:

<u>Clinical outcomes and process of care measures</u> (e.g. number of hospital contacts including admissions, clinic appointments, phone calls with hospital staff and changes to supportive medications and chemotherapy dose change).

Patient-reported outcomes

We will assess overall quality of life using validated questionnaires and appropriate subscales

We will also assess participants' views of their ability to manage and control their treatment related side effects with a number of measures assessing self-efficacy and patient activation.

Costs to patients and the NHS


Resource use will be assessed using patient questionnaires detailing contacts with GPs/community services, hospital visits and patient incurred costs.

Patient and staff interviews

Semi-structured staff, patients and carer interviews will be conducted to explore experiences of using the eRAPID intervention and any recommendations for improvement.

All participants will be asked to complete study measures at baseline, 6, 12 and 18 weeks.

Figure 3. eRAPID RCT diagram



7. Frequently asked questions

Below are some commonly asked questions about eRAPID.

What is expected of me during the eRAPID study?

Members of staff will be using the eRAPID patient information in different ways during the study. We will be encouraging doctors and nurses who have consultations and chemotherapy review assessments with eRAPID participants to use the patient reported information during their discussions with patients.

A small number of staff will be sent email alerts when study participants report severe symptoms. These staff members will receive specific training from the study team and will be asked to record their response to alerts in PPM.

We hope other members of staff (such as nurse practitioners who take phone calls from patients) may also use the patient reported symptom information and we would like staff to record in PPM if they used the eRAPID information or if the patient mentions being on the study. This will help us identify if eRAPID is helping patients make decisions about managing their symptoms and contacting the hospital.

eRAPID is a research study and it is important that we gather feedback from both patient participants and staff on their views of this new system for collecting and using patient reported information. Therefore we will be asking staff for their views of eRAPID during the study, either by a brief questionnaire or interview to determine how eRAPID is being used and suggestions for improvements.

Will eRAPID replace routine consultations and contacts with hospital staff?

eRAPID is not a replacement for usual care. The aim is for eRAPID to become an additional tool to assist with clinical decision making and patient symptom monitoring over time.

Will having to access results and discussing them with patients add to the consultation time?

Our previous research using patient reported data was in oncology clinics demonstrated that consultations times were not significantly increased in length. We hope that the patient reported

data collected in eRAPID will help make consultations efficient as the information can be used to assist with identify key problems and aid communication about symptoms and adverse events.

Will research staff be available if I have issues with accessing patient information in PPM?

During the study the research team will be recruiting and following up study participants in outpatients and day case wards. Please feel free to ask any of the team for help or advice if you are experiencing any issues. Alternatively you can contact the team using the number or email address below and we will aim to respond to your query as soon as possible (during normal working hours).

What do I do if a patient asks for help using eRAPID?

It is the responsibility of the research team to train participants in logging in and using the eRAPID online system. If a study participant is having problems accessing or using eRAPID then please ask them to contact the research team using the phone number or email address provided in the participant user guide and login postcard.

Is the information patients provide on the internet secure?

The answers patients provide to the symptom questionnaire during the eRAPID study will be linked to their electronic health record in PPM and the clinical staff will be able to access these. The answers provided will also be stored on secure databases within the University of Leeds, but they will be <u>anonymous and confidential</u>.

The research team:
Professor Galina Velikova, Chief Investigator
Kate Absolom, Senior Research Fellow Andrea Gibson, Research Sister Marie Holmes, Research Assistant Beverly Horne, Senior Research Nurse Zoe Rogers, Research Assistant Lorraine Warrington, Research Assistant
To contact us please:
Email: Telephone:


Figure 2: Staff training manual



Accessing eRAPID patient symptom reports on PPM


In the patient browser:

- 1) Find the patient.
- 2) Ensure the "Birth" event is selected in the left-hand events screen
- The "QTool" tab will appear in the righthand panel. Click on this to bring up the questionnaire responses.
- Ensure the correct trial "eRAPID RCT in systemic therapy" is selected.



You can then:

- View patient's responses in graph form.
- 2) View the results in tabulated form.
- Print results by scrolling to the bottom of the page and clicking "Print view".
- You can then use the right click on the mouse and select "Print".



Version 1.1




Accessing the eRAPID patient alerts report in PPM

At PPM Switchboard (first time)

- 1) Select 'Reports'
- Select 'External' tab
- Expand 'QTool' folder
- 4) Select 'QTool Alerts from Questionnaires'






After you have accessed the reports once, you can follow these steps thereafter which will be quicker.

At PPM Switchboard

- 1) Locate 'Recent Reports'
- Select 'QTool Alerts from Questionnaires'




Accessing eRAPID patient symptom reports and alert details

Qtool: Alerts From Questionnaires

From alert report

- Click on patients
 name to link to
 patients record and
 QTool results.
- The "QTool" tab will appear in the righthand panel. Click on this to bring up the questionnaire responses.
- Ensure the correct trial "eRAPID RCT in systemic cancer treatment" is selected.
- You can view results in graph or tabulated form by clicking on the tabs.



N.B. (1). Items in blue are clickable hyperlinks to the relevant PPM record (the PatientID links the subject to their relevant trial episode - click on PPM QTool tab to see QTi.
(2). The QTool Paticipant Name lookup list is filtered by the Specify a trial value. The default value is 'All'

V1.1 04/02/2015




Figure 3: One page staff prompt sheets

Formal training consisted of one on one sessions and group sessions including power point presentations and practical demonstrations in accessing the results within the EHR.

Informal training involved the research team attending clinic sessions offering ad hoc refresher sessions and introductions for new clinical staff members.

All clinical staff who received formal training completed an evaluation form which was evaluated by the research staff to inform changes to training. This ensured the training remained relevant and easily accessible.




Figure 4: Staff training evaluation form

Attendance certificates signed by the P.I. were provided for staff to add to their training portfolio.



Figure 5: Attendance certificate

Key personnel within the clinical teams were identified as 'eRAPID Champions'. Regular communication with these staff members contributed to continued staff engagement and fostered an environment of collaboration.

Development of eRAPID staff eLearning module

Based on feedback from staff interviews following the pilot study an eLearning package was developed in 2016 which was available online in December 2017. The resource was made available via a hyperlink from within the QTool symptom report section of the EHR at Leeds.

https://onlinecourses.leeds.ac.uk/eRAPID_training/index.html

Articulate software was used as the platform for the module (following a suggestion form co-applicant Dr Liz Glidewell). Key members of the research team worked in collaboration with Liz Glidewell to develop an overview/story board outline for the content of the training; though this was shaped by what was technically feasible to create and display within the software package.

The content and its presentations was guided by fundamental theories of adult learning¹ and built on a previous interactive staff training course we had piloted in Leeds². Clinical and research staff reviewed the content prior to online publication and amendments made accordingly.


The eLearning package consists of seven individual sections which the user can access in any order depending on time constraints and specific learning needs:

- Introduction to eRAPID
- How do I access and use the eRAPID symptoms report?
- eRAPID patient data in practice (clinical vignettes of a breast, colorectal and gynae cancer patient along with complementary QTool symptoms reports based on real-life patient case studies)
- Co-development of eRAPID with staff and patients
- How are we evaluating eRAPID?
- What is the value of Patient Reported Outcomes Measures (PROMs)
- eRAPID quiz.


The main didactic elements of the eLearning covers the purpose of eRAPID, practical steps for accessing results in the EHR and basic information on PROMs

and evidence supporting their use in cancer care. In addition the interactive case studies give the user an opportunity to reflect on the interpretation of example symptom reports and about how this might add to understanding the patient experience and guide the focus on a clinical consultation.

The eLearning allows flexibility in how the training can be delivered including an opportunity for blended learning (to supplement face-to-face training) or used as a standalone resource as needed (supporting self-directed learning).




A) Front main menu




B) How to access patient results in EHR




C) Clinical nurse specialist discussing eRAPID with PI




D) Patient comments on using eRAPID




E) Example of a case study



F) Example of patient results in EHR



G) Example of patient free text comments in EHR



H) eRAPID Quiz

Figure 6: Screenshots from eRAPID eLearning module

References

- 1. Kaufman DM. ABC of learning and teaching in medicine Applying educational theory in practice. *Bmj-Brit Med J* 2003;**326**:213-6. https://doi.org/DOI 10.1136/bmj.326.7382.213
- 2. Santana MJ, Haverman L, Absolom K, Takeuchi E, Feeny D, Grootenhuis M, et al. Training clinicians in how to use patient-reported outcome measures in routine clinical practice. *Quality of Life Research* 2015;**24**:1707-18. https://doi.org/10.1007/s11136-014-0903-5